Home » Clinical development » Elpida Therapeutics: Accelerating gene therapies for ultra‑rare neurodegenerative diseases
Elpida Therapeutics: Accelerating gene therapies for ultra‑rare neurodegenerative diseases

Research area:

Rare disease

Disease:

Spastic Paraplegia type 50 (SPG50), Neuronal ceroid lipofuscinosis 7 (CLN7 Batten disease), Charcot–Marie–Tooth disease type 4J (CMT4J).

Intervention:

Therapeutics – ATMP

Phase:

Funding awarded to

Elpida Therapeutics

Visit this trial’s project page

Related news

Dementia Consortium funds Manchester based team targeting immune system in search for new dementia treatments

Read more: Dementia Consortium funds Manchester based team targeting immune system in search for new dementia treatments

MRC Technology invests £7 million to expand its diagnostics research capability in Scotland

Read more: MRC Technology invests £7 million to expand its diagnostics research capability in Scotland

UK Drug Discovery Consortium symposium

Read more: UK Drug Discovery Consortium symposium